0 item(s) - $0.00
You have no items in your shopping cart.


Ranitidine raxide

How Do you take ranitidine raxide?

Gulp down the tablet without biting. Ranitidine can be brought with or without food.To avoid acid reflux and corrosive heartburn, take ranitidine 30-a hour prior to eating sustenance or drinking refreshments that can bring about indigestion.Do not take more than 2 tablets in 24 hours unless coordinated by your specialist.

What amount of ranitidine would you be able to take in a day?

For GERD and ulcers: The common dosage is 150 milligrams (mg) twice every day or 300 mg at sleep time. The support dosage is typically 150 mg a day. For acid reflux: The run of the mill measurement is 75 to 150 mg once every day or twice day by day, taken 30 to a hour prior to a dinner or refreshment that can bring about indigestion.

Is ranitidine viewed as an acid neutralizer?

Ranitidine may bring about languor or tipsiness. Try not to drive or work different perilous hardware until the impact of the medication has been resolved. Since smoking is a hazard consider peptic ulcer illness, quit smoking if conceivable. Takingranitidine with stomach settling agents could counteract assimilation of the ranitidine.

Will ranitidine be purchased over the counter?

Ranitidine might be brought with or without sustenance. At the point when utilized over-the-counter to treat corrosive acid reflux, indigestion, or harsh or furious stomach, the typical measurement for grown-ups and youngsters 16 years old or more seasoned is 75 mg to 150 mg taken when side effects show up.


Store at room temperature (15 to 30°C). Shield from light.


Ranitidine eases and treats the copying and distress of indigestion, corrosive heartburn, furious and harsh stomach, connected with abundance corrosive giving quick and successful alleviation. Ranitidine tablets lessens and controls stomach corrosive for up to 12 hours, day or night.


150 mg: Grown-ups and kids 16 years and more seasoned: One tablet ought to be taken when indications show up, day or night. In the event that side effects hold on for over 1 hour or return following 60 minutes, a moment tablet might be taken. The most extreme measurement is 2 tablets (300 mg ranitidine) in a 24 hour time span. For avoidance of side effects brought on by devouring nourishment or drinks, 1 tablet ought to be taken 30 to a hour prior to eating a supper or expending refreshments anticipated that would bring about side effects.


If you are taking a professionally prescribed solution for stomach ulcer, experience issues gulping or determined stomach inconvenience, have kidney illness, or are pregnant or bosom nourishing, counsel your specialist before taking this item. Keep out of the compass of kids.

Sedate Cooperations/Contraindications:

    • Contraindicated in patients known to have excessive touchiness to any of the segment of the arrangement. Ranitidine may cover side effects connected with carcinoma of the stomach and, along these lines, may defer conclusion of that condition. Ranitidine may accelerate intense porphyritic assaults, in this manner it ought to be dodged in patients with a past filled with intense porphyria. Ranitidine is discharged through kidneys and, within the sight of extreme renal hindrance, plasma levels of ranitidine are expanded and disposal delayed. Simultaneous organization of acid neutralizers and ranitidine may diminish retention of ranitidine; in this way, stomach settling agents ought not be taken inside 1/2 - 1 hour of ranitidine ingestion.
    • Concurrent organization of ketokonazole and ranitidine may bring about lessening of the ingestion of ketoconazole. Ranitidine ought not be taken for at any rate for 2 hours after ketoconazole. High measurements of sucralfate (2 grams) may lessen retention of ranitidine. It is prescribed to take sucralfate 2 hours after ranitidine organization.
    • Poisonous quality/Antagonistic Reactions:The most basic unfriendly occasions incorporate cerebral pain, sickness, heaving and looseness of the bowels. It can likewise bring about wooziness, vertigo, mental trips (prevalently in seriously sick elderly patients), untimely ventricular beats, bradycardia, atrioventricular piece, transient and reversible changes of liver capacity tests, hepatitis with or without jaundice. Uncommon instances of agranulocytosis and pancytopenia, once in a while with marrow hypoplasia or aplasia, rash, little increment in serum creatinine, and intense pancreatitis have been accounted for. Excessive touchiness responses can happen including bronchospasm, hypersensitivity, hypotension and angioneurotic edema.
    • Indications and Treatment of Overdose:There is no experience to date with consider overdosage. The typical measures to expel unabsorbed medicate from the gastrointestinal tract (counting initiated charcoal or syrup of ipecac), clinical observing and steady treatment ought to be utilized. Likewise, if require, the medication can be expelled from the plasma by haemodialysis. Up to 6g every day has been managed without untoward impact.

For the Consumer

Applies to ranitidine: oral solution, oral tablets and tablets for, oral tablets effervescent for solution, parenteral injection, parenteral injection for iv infusion only

Side effects include:

Oral or parenteral therapy: Headache, sometimes severe.

IM therapy: Transient pain at injection site.

IV therapy: Transient local burning or itching.

For Healthcare Professionals

Applies to ranitidine: compounding powder, injectable solution, intravenous solution, oral capsule, oral granule effervescent, oral syrup, oral tablet, oral tablet effervescent


Ranitidine is generally well tolerated.


Gastrointestinal side effects have included constipation, nausea/vomiting, diarrhea, abdominal pain, and rare reports of pancreatitis. Rebound acid hypersecretion has been reported after discontinuation of therapy. A case report of coinfection with Giardia lamblia and Clostridium difficile has been attributed to the achlorhydria induced by ranitidine predisposing the patient to the enteric infection.


Cardiovascular side effects have rarely included tachycardia, bradycardia, atrioventricular block, and premature ventricular beats. Several cases of bradycardia following intravenous administration of ranitidine have been reported. Ranitidine-induced bradycardia may be due to a rise in the serum histamine concentration or due to a direct effect of ranitidine on cardiac H2 receptors.

Nervous system

Nervous system side effects have been reported rarely. These have included headache (sometimes severe), somnolence, dizziness, malaise, and vertigo. Reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Hostility, mania, mental status changes, dystonia, reversible involuntary motor disturbances have also been reported.

The mechanism  by which ranitidine induces mental status changes is not well established but appears to involve increased serum concentrations of ranitidine. Renal dysfunction, advanced age, and critical illness appear to be associated with an increased risk of central nervous system toxicity. Onset of symptoms is typically within the first few weeks of therapy, but may be delayed. Following discontinuation of ranitidine, mental status usually normalizes over several days


Two cases of toxic epidermal necrolysis have been reported in patients with underlying idiopathic thrombocytopenia purpura. A 72-year-old male also experienced a photosensitivity reaction that resolved after ranitidine was discontinued.

Dermatologic side effects have included alopecia, rash, pruritus, contact dermatitis, erythema multiforme, cutaneous vasculitis, and toxic epidermal necrolysis.


Musculoskeletal side effects have included arthralgias and myalgias.


Overall, serious hepatotoxicity due to ranitidine is rare. Hepatocellular, hepatocanalicular, and mixed-type injury have been reported. In most cases, hepatotoxicity has been associated with fever, chills, nausea, and occasionally rash and eosinophilia, with onset of symptoms early in the course of therapy. Such symptomatology is suggestive of a hypersensitivity etiology. The majority of cases resolve following discontinuation of ranitidine therapy although, at least two fatalities have been reported.

In a study with healthy volunteers , SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg intravenously four times daily for 7 days, and in 4 of 24 subjects receiving 50 mg intravenously four times daily for 5 days

Hepatic side effects have included transient and minor increases in serum transaminases, which may be important in patients with liver disease. There are rare reports of ranitidine-induced hepatitis with or without jaundice, one case of subfulminant hepatitis with a fatal outcome, and very rare cases of acute interstitial nephritis.


Other reported side effects have included tiredness and one case of aseptic meningitis.


Hypersensitivity side effects have included rash, urticaria, bronchospasm, fever, eosinophilia, angioneurotic edema, acute eosinophilic pneumonia and anaphylaxis. Vasculitis associated with immune complexes has also been reported.


Renal side effects have included mild elevations in serum creatinine. Rare cases of interstitial nephritis and Fanconi's syndrome have been reported.


Respiratory side effects have included an increased risk of developing pneumonia in patients taking H2 receptor antagonists versus those who had stopped treatment. However, a causal relationship has not been established.


Ocular side effects have included blurred vision and increased intraocular pressure in a patient with a history of glaucoma.


Hematologic side effects have included leukopenia, granulocytopenia, and thrombocytopenia in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, aplastic anemia, and acquired immune hemolytic anemia have been reported.

Serious hematologic abnormalities are rare. Patients with renal dysfunction or those who are critically ill may be at increased risk. While the mechanism of bone marrow toxicity is unknown, ranitidine concentration-dependent inhibition of hematopoietic progenitor cell activity and hypersensitivity have both been proposed. Hematologic abnormalities typically resolve upon discontinuation of ranitidinetherapy.

Cases of ranitidine-induced thrombocytopenia are typically immune-mediated.


Endocrine side effects have been reported rarely. These have included gynecomastia, impotence, and loss of libido in male patients, although, the incidence was similar to that in the general population. Hyperprolactinemia, amenorrhea, reductions in circulating levothyroxine and hypergastrinemia have also been reported.

Ranitidine does not possess antiandrogenic properties nor has it been associated with significant changes in pituitary hormone concentrations under study conditions. However, increases in prolactin serum concentrations following administration of high doses as well as decreases in levothyroxine serum concentrations during short-term therapy have been reported. Thyroid hormone levels are not affected during long-term therapy.

For more information visit us our website: